Kodosil Bio LLC.

Kodosil Bio focuses on developing treatments with antibodies for bowel disease and cancers and was formed as the result of a strategic licensing agreement between BioMotiv and BioAtla.

BioMotiv as a company is interested in licensing technologies and sourcing products from preclinical through early clinical stages of development, while BioAlta provides its proprietary platform for identifying and developing promising therapeutics antibodies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://kodosil.squarespace.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
20600 Chagrin Blvd., Suite 210,OH,44122-5344
Cleveland
United States
Email
Contact Number
+1 216-455-3200

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Pipeline

IL-22 antibody is directed at a novel validated target in the TH22 cell/IL-22 pathway, and has high expression levels in colorectal cancer (CRC) patients.

In Feb 2014, BioAlta grants Kodosil Bio (promoted by BioMotiv) an exclusive worldwide development rights to IL-22 antibody for inflammatory bowel diseases (IBD) and oncologic indications.